A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial. uri icon

authors

  • Dalane W Kitzman, MD
  • Shah, Sanjiv J
  • Lewis, Gregory D
  • Pandey, Ambarish
  • Borlaug, Barry A
  • Sauer, Andrew J
  • Litwin, Sheldon E
  • Sharma, Kavita
  • Jorkasky, Diane K
  • Khan, Shaharyar

publication date

  • June 26, 2024